AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02485574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal lumbar interbody arthrodesis
Description: Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
Study NCT03107325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modification in acquisition protocol
Description: Participants will be asked to be imaged at an additional time point.
Study NCT03107325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F-18 Fluorodeoxyglucose
Description: Participants will be asked to be imaged at an additional time point during an FDG PET study
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Intravenous (IV), 20 mg, Day1 and Day 5
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept More Intensive (MI)
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Less Intensive (LI)
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
Study NCT00555321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
Study NCT02609750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
Study NCT03392883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
Study NCT03416920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellframe
Description: Wellframe mobile phone app
Study NCT00592228 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cypher, Taxus or Endeavor
Description: percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group
Study NCT00137046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study NCT00137046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study NCT00784992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endonasal dacryocystorhinostomy
Description: The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted.
Study NCT01066533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping and covering the exposed pulp
Description: In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
Study NCT01066533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping and covering the exposed pulp
Description: In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
Study NCT01878058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI Scan
Description: Patient will receive an additional MRI scan in addition to their standard of care imaging
Study NCT05329272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training Intervention (VRCTI)
Description: The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
Study NCT03017651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-supplement 1
Description: 1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
Study NCT03017651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OM3-supplement 2
Description: 1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
Study NCT03298594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: specific cervicograph
Study NCT01635192 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide.
Study NCT01635192 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
Study NCT03238508 — intervention group
Intervention type: PROCEDURE
Intervention: Deferred stenting
Description: Previously described
Study NCT02345382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Study NCT02483546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laerdal®
Description: simulation- based educational intervention
Study NCT02483546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: huma patient based training
Description: Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
Study NCT02483546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditionally teaching
Description: Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
Study NCT01307800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT01546454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol-Levonorgestrel combination
Description: 0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
Study NCT01546454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: single 22.5 mg subcutaneous depot suspension
Study NCT01546454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 0.05 to 0.3 mg transdermal daily for 26 days
Study NCT01546454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 50 to 100 mg vaginal suppositories twice daily for 13 days
Study NCT00535665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 14 days apart: 5 microgram per dose
Study NCT00535665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 5 microgram per dose
Study NCT00535665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 10 microgram per dose
Study NCT00535665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 15 microgram per dose
Study NCT03834454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
Study NCT03834454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
Study NCT04312360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopy with metronidazole and fosfomycin disodium
Description: therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
Study NCT03676595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study NCT03676595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study NCT03240250 — intervention group
Intervention type: PROCEDURE
Intervention: VATS uni-portal lobectomy and lymphoadenectomy
Description: VATS uni-portal lobectomy and lymphoadenectomy
Study NCT03240250 — intervention group
Intervention type: PROCEDURE
Intervention: VATS three-portal lobectomy and lymphoadenectomy
Description: VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
Study NCT03568253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries treatment
Description: Treatment by Bulk fil composite after randomization of the tooth
Study NCT03568253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries treatment
Description: Treatment by High viscosity glass ionomer after randomization of the tooth
Study NCT01170065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Intermediate dose BIBF 1120 twice daily
Study NCT01170065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: High dose BIBF 1120 twice daily
Study NCT01170065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Low dose BIBF 1120 twice daily
Study NCT01170065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Low dose BIBF 1120 once daily
Study NCT03730961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous administration
Study NCT03730961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Intravenous administration
Study NCT03730961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration
Study NCT03241771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naloxone Navigator 1.0
Description: Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
Study NCT01913028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
Study NCT01913028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
Study NCT03005301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent electroacupuncture instrument
Description: Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes.
Study NCT03005301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hwato electroacupuncture instrument
Description: Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes.
Study NCT03897296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution anorectal manometry, water perfused catheter
Description: High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
Study NCT03065101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trigen Intertan
Description: While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
Study NCT03065101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-Surgery Follow Up
Description: The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
Study NCT03065101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sliding Hip Screw
Description: Sliding Hip Screw
Study NCT00326989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy
Study NCT01288469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: One subcutaneous (SC) injection in the abdomen only.
Study NCT01288469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: One SC injection in the abdomen only.
Study NCT01288469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Over-encapsulated tablet orally once daily in the evening with dinner.
Study NCT01288469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Over-encapsulated tablet orally once daily in the evening with dinner.
Study NCT01288469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for atorvastatin)
Description: One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
Study NCT01680523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Description: Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
Study NCT01680523 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tailored adjuvant therapy
Description: After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
Study NCT01680523 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Primary chemoradiation therapy
Description: Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
Study NCT04014842 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RapidShock
Description: Use of the Reconfirmation Analysis Mode algorithm